🔴 Neurosense Therapeutics is trading 10.47% down today after announcing a 1-for-20 reverse share split

Neurosense Therapeutics is trading 10.47% down now at $0.36, with its company-specific reverse split the clearest explanation for the decline.

• The consolidation will reduce outstanding shares from 37,938,036 to approximately 1,896,902; post-split trading is scheduled to begin September 14, 2026.
• The split was announced September 9, 2026.
• Selling pressure appears to be continuing ahead of implementation. Broader markets are also lower following hotter August producer-price inflation, while weaker market sentiment may be adding pressure.